Scientific Sessions 2026 Daily News: Sunday, Nov. 8

There is nothing more heartbreaking than a squandered opportunity or a missed chance. Eric Topol, MD, founder and director of the Scripps Research Translational Institute, urged attendees at the opening session of Scientific Sessions 2026 to embrace every missed opportunity as a chance to discover more during “Missed Opportunities in Cardiovascular Medicine.” “This is going to be quick,” he joked. “It’s going to be like Last Week Tonight With John Oliver.” Topol, who is one of the most cited researchers in medicine and author of Deep Medicine and Super Agers, riffed through multiple cardiovascular conditions, tests and devices that could deliver cardiovascular discovery Sunday Nov. 8, 2026 Daily News #ScientificSessions26 Science & Technology Hall Map inside Cardiovascular risk in girls and women is shaped by more than cholesterol and blood pressure readings. Key hormonal transitions create critical windows for identifying and addressing future heart disease risk. Karen Florio, DO, MPH, detailed the importance of a life-course approach to cardiovascular care during Saturday’s session, “The Ups and Downs of Sex Hormones: Critical Windows for Cardiovascular Health in Girls and Women.” From puberty to pregnancy to menopause, Florio emphasized that reproductive health events should be viewed as cardiovascular health events, and that the implications extend well beyond the immediate stage of life in which they occur. Florio is an associate professor and vice chair of patient safety and quality, and director of the maternal-fetal medicine fellowship at the University of Missouri School of Medicine in Columbia. “It’s important to understand how the interpretation and management of blood pressure changes across the peripartum window, and why those differences matter for continuity of care,” Florio said during her presentation, “The Peripartum Window: How Do the Definitions and Treatment Targets for Hypertension Differ?” Before pregnancy, Florio said, adult hypertension begins at a systolic pressure of 130 mm Hg and/ or a diastolic pressure of 80 mm Hg, with an overall treatment goal of less than 130/80 mm Hg, according to the American Heart Association/ American College of Cardiology guidelines. During pregnancy, the American College of Obstetricians and Gynecologists (ACOG) guidelines set the diagnostic threshold at a systolic pressure of 140 mm Hg or a diastolic pressure of 90 mm Hg. For chronic hypertension in pregnancy, ACOG recommends initiating or adjusting medication at 140/90 mm Hg, while the Society for Maternal-Fetal Medicine recommends a treatment goal below 140/90 mm Hg. Distinguishing a diagnostic threshold, a threshold for starting treatment and a treatment See WOMEN, page 16 Women’s heart health: Every stage matters Hormonal transitions offer opportunities to identify cardiovascular risks and intervene earlier. Today at Sessions 4 Late-Breaking Science: Lessons from landmark trials 3 Connecting the dots in cardio-kidneymetabolic 5 The hidden risks after PE 8 Inside Simulation Zone 17 See OPENING SESSION, page 7 Using mRNA to treat cardiovascular disease 6 Cardiac CT offers a clearer picture of CVD 13 Karen Florio, DO, MPH Remember to wear your sneakers tomorrow for Sneakers Day Nobel Laureate: Outcomes at the end of the road not taken 8 Eric J. Topol, MD Keynote speaker: Missed opportunities could lead to great discoveries

Booth #3243 Saturday, Nov. 7 | Sunday, Nov. 8 9 a.m.-4:30 p.m. (or until tests run out) Elevated uACR is an independent predictor of chronic kidney disease progression, cardiovascular events, and all-cause mortality. Fewer than 20% of U.S. adults with diabetes or hypertension receive routine uACR testing. uACR testing supported by: Paid Advertisement Testing and Awareness uACR

3 #ScientificSessions26 ScientificSessions.org Ziltivekimab did not reduce cardiovascular event rates in patients with CKD Inflammation remains an important contributor to heart disease and stroke and a target for intervention. Large-scale trials have demonstrated that targeting inflammation by inhibiting interleukin 1 (IL-1) or with colchicine can significantly reduce cardiovascular event rates in select individuals with cardiovascular disease. In the Primary Report of the Ziltivekimab Cardiovascular Outcomes Study, the ZEUS trial, researchers sought to find out if ziltivekimab, a monoclonal antibody targeting interleukin-6 (IL-6), reduced cardiovascular events in patients with chronic kidney disease (CKD), atherosclerotic cardiovascular disease (ASCVD) and cardiovascular inflammation, defined by high-sensitivity C-reactive protein (CRP). The study, spanning 757 sites in 38 countries, randomized 6,395 participants with known atherosclerotic cardiovascular disease, chronic kidney disease and residual inflammatory risk defined as elevated high sensitivity C-reactive protein (hsCRP > 2 mg/L) to the IL-6 inhibitor ziltivekimab, 15 mg given subcutaneously monthly versus placebo. Mean patient age was 69.4, and approximately 28% were women. The placebo-adjusted percent change from baseline at 24 months with ziltivekimab was -76% for free IL-6 and -64% for hsCRP. Yet, during a median follow-up of 33 months, the primary composite cardiovascular endpoint of nonfatal myocardial infarction (MI), nonfatal stroke or cardiovascular death occurred in 561 participants (17.6%) in the ziltivekimab group and 565 (17.7%) in the placebo group (HR=0.99; 95% CI, 0.88 to 1.11; p=0.84). Paul Ridker, MD, MPH “We hypothesize that a major reason for neutrality in ZEUS is that the severe underlying disease in these participants may have been nonmodifiable,” said Paul Ridker, MD, MPH, Eugene Braunwald Professor of Medicine at Harvard Medical School and director of the Center for Cardiovascular Disease Prevention Physician at Brigham and Women’s Hospital in Boston. “The horse may already have been out of the barn.” Although ziltivekimab did not improve cardiovascular outcomes or reduce overall mortality, Ridker noted that cardiovascular inflammation is highly prevalent and remains a mechanistically compelling therapeutic target beyond lipid lowering. “Individuals with elevated hsCRP need strong recommendations for preventive care,” Ridker said, emphasizing that in addition to diet, exercise and smoking cessation, all of which lower hsCRP, statins, colchicine, canakinumab and GLP1RAs positively impact patients with residual inflammatory risk. Meanwhile, several promising opportunities for downstream IL-6 inhibition remain in earlier modifiable disease as well as multiple opportunities for direct targeting of the upstream NLRP3 inflammasome. “It’s an exciting time for inflammation and heart disease,” he said. The study was published in the New England Journal of Medicine following the presentation. Novel antisense oligonucleotide did not reduce risk of major cardiovascular events in secondary prevention Lp(a) is a genetically determined risk factor for atherosclerotic cardiovascular disease and aortic stenosis with no approved pharmacological treatments. Could pelacarsen, an antisense oligonucleotide (ASO) designed to degrade hepatic messenger RNA (mRNA) coding for apolipoprotein(a), reduce the risk of major adverse cardiovascular events in patients with high Lp(a) and established cardiovascular disease? That was the question asked in Pelacarsen and Cardiovascular Outcomes in Patients With High Lipoprotein(a). The double-blind, placebocontrolled phase 3 cardiovascular outcome trial randomized 8,322 patients with lipoprotein(a) ≥ 70 mg/dL (~148 nmol/L) at screening, stratified based on values ≥ 90 mg/dL (~192 nmol/L) with cardiovascular events three months to 10 years prior to enrollment. Patients were randomized 1:1 to pelascarsen 80 mg or placebo, selfadministered subcutaneously once a month at home at 797 sites in 42 countries from December 2019 to July 2022. Risk factor optimization with guideline-directed therapies was required, including lipidlowering and antihypertensive therapies during a 30- to 90-day period to strictly meet guidelines for secondary prevention. Patients were followed for a median follow-up duration of 4.7 years. The trial was event-driven until 993 primary endpoints accrued. The primary endpoint was a composite of four MACE, including cardiovascular death, nonfatal stroke, nonfatal MI and urgent coronary revascularization. After 12 months of treatment, pelacarsen reduced median Lp(a) levels by 77.7%, from 236 nmol/L to 64 nmol/L but did not meet its primary endpoint of reducing the risk of major cardiovascular events, compared to placebo. The HR for the primary endpoint was 1.02 in the full population and 1.00 for patients with an Lp(a) ≥ 90 mg/dL. Steven E. Nissen, MD, MACC “The Lp(a) HORIZON trial is not the end of the story. Although these results are disappointing, they provide scientific insights that help inform future research efforts,” said Steven E. Nissen, MD, MACC, chief academic officer at the Sydell and Arnold Miller Family Heart, Vascular & Thoracic Institute at the Cleveland Clinic in Ohio and the study chair. He noted that background therapy was optimized with LDL cholesterol Trial results presented in Saturday’s Late-Breaking Science session revealed surprising findings on novel approaches to reduce cardiovascular disease risk. The results found: • Novel IL-6 inhibitor did not reduce adverse cardiovascular outcomes in patients with CKD, ASCVD and cardiovascular inflammation. • Novel lipoprotein(a) therapy did not reduce major adverse cardiovascular events (MACE) risk. • Extended analysis of lipoprotein(a) HORIZON trial showed consistent results with prespecified primary analysis. Lessons from landmark trials See LANDMARK TRIALS, page 18

4 SCIENTIFIC SESSIONS DAILY NEWS | Sunday, Nov. 8, 2026 Located in the Science & Technology Hall, Heart Hub, Booth 1 HeartQuarters Discover American Heart Association initiatives at Science & Technology Hall Hours Saturday, Nov. 7 9 a.m.-4:30 p.m. Sunday, Nov. 8 9 a.m.-4:30 p.m. Monday, Nov. 9 9 a.m.-3 p.m. American Heart Association AI TORCH American Heart Association International Initiatives CPR & First Aid, ECC Lifelong Learning Patient and Caregiver Guidance and Support Professional Education Hub™ Research Funding & Peer Review Scientific Journals Target: Aortic Stenosis Target: Hypertrophic CardiomyopathyTM The Heart Valve InitiativeTM Learn more about American Heart Association initiatives. Try the claw machine to win a prize! Today at Sessions All sessions are located at the McCormick Place Convention Center unless otherwise noted. Late-Breaking Science and Featured Sessions LBS.ID.02 | LBS In-Depth 2 9:45–11 a.m. | N230B CD.ME.03 | Nobel Laureate Address 9:45–11 a.m. | S100A PS | Presidential Session and Conner Lecture 1:30–3 p.m. | Center Stage, North Hall, Level 3 JRNL.09 | How to Write Like a Nobel Laureate: An American Heart Association Journal Session 3:15–4:30 p.m. | S100A LBS.04 | Late-Breaking Science: Innovations to Optimize Arrhythmia Care 3:30–4:45 p.m. | Center Stage, North Hall, Level 3 Guideline Programming CK.ME.02 | Bringing the AHA/ACC/ ADA/ASN Cardiovascular-KidneyMetabolic Syndrome Guideline to Life 8–9:15 a.m. | S105ABC BH.CVS.08 | A New Era in Stroke Rehabilitation: Evidence, Innovation and Patient Impact 3:30–4:45 p.m. | S105ABC Global Impact GL-IMP.06 | Dyslipidemia as a Global Epidemic: Why Guidelines Must Travel Well 3:30–4:45 p.m. | N139 Special Sessions GE.CVS.08 | I Ordered the Test, Now What? A Practical Guide to Cardiovascular Genetics for the General Cardiologist* 8–9:15 a.m. | Special Session, North Hall, Level 3 HF.CVS.06 | HFpEF: From Bench to Bedside – Translating Science Into Clinical Care* 9:45–11 a.m. | Special Session, North Hall, Level 3 NR.CVS.06 | Frailty in Cardiovascular Disease: An Evolving Landscape From Old to Young* 3:30–4:45 p.m. | Special Session, North Hall, Level 3 View the Industry Programming Guide for today’s events. Please see the Experience Scientific Sessions Program and the mobile app for all programming. *Not a CE accredited session.

5 #ScientificSessions26 ScientificSessions.org As guidelines across myriad medical specialties expand and evolve, more are encouraging an integrative approach to patient screening. That’s the case for the 2026 cardiovascularkidney-metabolic (CKM) syndrome guideline, jointly developed by the American Heart Association, the American College of Cardiology, the American Diabetes Association and the American Society of Nephrology. Designed to provide guidance for managing some of the nation’s most common and interconnected chronic diseases, the guideline is the foundation for the Sunday session “Bringing the AHA/ACC/ADA/ASN Cardiovascular-Kidney-Metabolic Syndrome Guideline to Life.” At the session, Janani Rangaswami, MD, FAHA, FACP, will present “Saving Kidneys, Hearts and Lives: Best Practices for CKD Management in CKM Syndrome.” “One of the big elements of guideline framework is emphasizing that metabolic factors like obesity and diabetes, kidney diseases and cardiovascular disease are deeply interconnected,” said Rangaswami, a professor of medicine at the George Washington University School of Medicine & Health Sciences in Washington, D.C., and past chair of the Council on the Kidney in Cardiovascular Disease of the American Heart Association. “We have this big opportunity to screen for kidney disease, which is a central piece of the CKM syndrome construct, and to implement foundational therapies with cardioprotective benefits that also have kidney protective benefits.” Connecting the dots in cardio-kidney-metabolic New guideline emphasizes interdisciplinary approach for multi-organ patient care. Follow these steps to claim your CE credit(s) for Scientific Sessions 2026: 1. Go to education.heart.org. 2. Click Sign In/Sign Up and sign in with your Username and Password. 3. Click on your name in the upper right-hand corner and select My Library. 4. Select your activity. 5. Review the About this Survey section. 6. Click Start Survey to complete the evaluation. 7. Once completed, click the Submit and Return to Detail Page buttons. 8. To download a non-accredited completion certificate, click Download Certificate. 9. Claim your CE credit by clicking Claim CE. 10. Enter all required information and click Submit. 11. Click on your name in the upper right-hand corner and select My Account. 12. Click CE Details. 13. Click the View CE Claim(s) drop-down arrow. 14. Click the Download Icon to download your CE Certificate. Need assistance? For customer support, call 1-877-340-9899 (Monday-Friday, 8 a.m.–6 p.m. CST), or email education.help@email.education. heart.org. Janani Rangaswami, MD, FAHA, FACP See CKM GUIDELINE, page 15 Earn credit for your attendance! UPCOMING SESSION Bringing the AHA/ACC/ADA/ASN Cardiovascular-Kidney-Metabolic Syndrome Guideline to Life 8–9:15 a.m. | Sunday, Nov. 8 S105ABC American Heart Association 2026 For more information, please contact AskFirst@askbio.com or scan the QR code This event is not part of the official Scientific Sessions Conference 2026 as planned by the American Heart Association Committee on Scientific Sessions Programming. Disclaimer: AB-1002 is an investigational product and is not approved by the FDA, EMA, or any other health authority. AB-1002's safety and efficacy are not established. PAID ADVERTISEMENT • Timothy Henry, MD, The Christ Hospital, Cincinnati, OH, USA • Gavin Oudit, MD, PhD, University of Alberta, Edmonton, AB, Canada • JoAnn Lindenfeld, MD, Vanderbilt University Medical Center, Nashville, TN, USA • Yuri Kim, MD, PhD, Brigham and Women's Hospital, Boston, MA, USA Date: Sunday, November 8, 2026 Time: 11:15 a.m. – 12:00 p.m. CT Location: Learning Studio 3 Visit us at Booth 1908 Join us for a dynamic panel discussion, Q&A and lunch Gene Therapy for the Failing Heart: Early Clinical Findings with Umiposgene Parvec (AB-1002) Heart failure remains a leading cause of morbidity and mortality worldwide despite advances in pharmacologic and device-based therapies. This session will explore an investigational gene therapy being evaluated for treatment of advanced heart failure, highlighting early clinical findings with umiposgene parvec (AB-1002). The presentation will discuss the potential of gene therapy to address underlying molecular dysfunction in patients with heart failure. Learning Studio Speakers: Moderated by Roger Hajjar, MD, Mass General Brigham, Cambridge, MA, USA ABE-0217

6 SCIENTIFIC SESSIONS DAILY NEWS | Sunday, Nov. 8, 2026 Advancing Care in HFmrEF/HFpEF: Optimizing Therapies for Better Outcomes Request a Presentation Today! spotlight.heart.org Heart Failure affects approximately 6.7 million Americans age 20 and older and the need for effective care management continues to grow. Empower your team to enhance care for patients with heart failure with mildly reduced ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF). LEARNING OBJECTIVES This program is sponsored by Bayer PAID ADVERTISEMENT © Copyright 2026 American Heart Association, Inc., a 501(c)(3) not-for-profit. All rights reserved. Unauthorized use prohibited. WF-1903575 9/26 • Early Treatment Initiation • Treatment Differentiation • HFmrEF/HFpEF Disease Burden • Reducing Residual Risk FREE GRAND ROUNDS EDUCATION IN PERSON OR VIRTUALLY Researchers are now refining modified mRNA therapies to deliver targeted treatments more precisely, potentially opening new avenues for cardiac repair and regeneration. Sunday’s session, “RNA Therapeutics for Cardiovascular Disease and Beyond,” will explore how these novel technologies and targeted therapies could deliver safe, precise treatments. It will also include a presentation from Lior Zangi, PhD, on mRNA therapeutic approaches. Nucleotide-modified mRNA (modRNA) usage has been a hot topic across medical specialties. During the COVID-19 pandemic, modified mRNA demonstrated its utility as a safe and effective vaccine platform. In cardiology, modified mRNA offers potential advantages for repairing damaged heart tissue, said Zangi, who holds the Chan Soon-Shiong Professorship in Cardiovascular Research and is a professor of cardiology and genetics and genomic sciences at the Icahn School of Medicine at Mount Sinai in New York. In his lecture, “Selective Modified mRNA Therapeutics for Cardiovascular Disease,” Zangi will share highlights from preclinical research and clinical trials, including recent advancements, emerging strategies and key takeaways. “I will discuss the lessons learned from previous clinical efforts, including the factors that may have limited [modRNA’s] therapeutic efficacy, and highlight how advances in mRNA design, delivery, tissue specificity and translational control have created new opportunities to improve outcomes,” Zangi said. Modified mRNA offers a transient method of gene delivery. Compared with traditional gene- and proteinbased approaches, Zangi said, it is easier to sequence, scale and manufacture and carries minimal risk of insertional mutagenesis because it does not permanently alter the genome. Modified mRNA is highly adaptable, allowing researchers to customize the amount, duration and cellular specificity of protein expression, he said. This adaptability could support applications ranging from vaccination and protein replacement to regenerative medicine and cancer therapy. However, Zangi said the therapy has limitations and is not suited to prolonged gene delivery because its effects are transient. “Unmodified or improperly formulated mRNA can activate innate immune responses, while the inherent instability of mRNA can limit its half-life and translational efficiency,” he said. “Effective in vivo delivery also remains a major obstacle, particularly for achieving tissue- and cellspecific targeting while minimizing accumulation in nontargeted organs.” To help address concerns like prolonged activity, dose-dependent toxicity and biodistribution variability, Zangi and others have developed Selective modRNA Translation systems (SMRTs) that promote cell-type-specific protein expression in cardiomyocytes or noncardiomyocyte populations. “Continued advances in mRNA chemistry, sequence engineering, translational control and targeted delivery are critical for improving the safety, specificity and therapeutic efficacy of mRNA-based medicines,” he said. Potential applications for SMRTs range from repairing heart tissue after myocardial infarction and promoting recovery from cardiovascular injury to treating chronic conditions such as ischemic heart disease. Using mRNA to treat cardiovascular disease mRNA is easier to sequence, scale and manufacture, and it carries fewer risks of insertional mutagenesis. Lior Zangi, PhD UPCOMING SESSION URNA Therapeutics for Cardiovascular Disease and Beyond 3:30–4:45 p.m. | Sunday, Nov. 8 S102A

7 #ScientificSessions26 ScientificSessions.org by taking advantage of accessible information. • Exercise activity. Topol cited activity as the No. 1 thing to promote youthful aging, especially of the cardiovascular system. He encouraged the audience to take detailed histories of each patient’s activities, creating an individualized plan for each person. • Sleep regularity and sleep quality. Second to exercise activity, Topol said sleep is highly correlated with cardiovascular favorable outcomes. • Polygenic risk scores. Using an independent assessment from family history and other risk factors, polygenic risk scores can predict the risk of coronary disease. “An exquisite definition of risk that we’re not using,” he said. • Genomic assessment: Topol questioned why the cardiovascular community was not conducting a genomic assessment for a number of conditions. The conditions included abnormally wide aortas, clonal hematopoiesis and aortic aneurysms. • Devices. He suggested the six-lead ECGs could provide “more insight about conduction disturbances, which you’re not going to get from a pulse.” It can be completed in just a few seconds in each patient, with or without taking their pulse. • Using AI for medical scan interpretation. Topol pointed to medical imaging such as chest X-rays, CT, mammography, echocardiograms and MRIs as obvious areas that AI could examine and provide detailed evidence of abnormalities. “Every single type of medical image has a rich embedment of data that is left on the table.” For example, he said a single chest X-ray is better than the atherosclerotic cardiovascular risk score. “Why aren’t we using it for patients as a way to assess their risk?” Topol advocated for the intelligent use of AI with ECGs to better diagnose at-risk patients. “AI is not being used to interpret cardiograms, except in a few health systems in this country, like Mayo Clinic,” Topol said. There is so much more that can be “derived from a cardiogram about, for example, future atrial fibrillation risk and future stroke risk in people in normal sinus rhythm.” Topol also pointed to mammograms and retinal scans as rich medical images that are being underused in gathering so much more information about cardiovascular health. “The retina, the most-rich medical image … looking at blood vessels and nerves in one photo, tells us about subclinical atherosclerosis. You can calculate the heart calcium score; you can predict heart attack, stroke risk. In identifying these missed opportunities, Topol insisted future discoveries are there for the taking by the cardiovascular community. “We can do this,” he said. Choose Your Case. Strengthen Your Clinical Strategy. Put the PREVENT Equations into practice. Cardiovascular-Kidney-Metabolic (CKM) Health Learning Lab is an innovative simulation experience where clinicians can rehearse meaningful cardiovascular care conversations with standardized patients before they happen in practice. Engage with patient scenarios that challenge you to integrate PREVENT risk assessment into the care of patients with CKM syndrome. Limited Seats. Lasting Impact. DAILY (SAT. - MON.), 9:15am – 1:45pm CST *Limited spots are available to ensure a high-quality experience. Register now and be part of this sought-after learning opportunity. The American Heart Association’s Cardiovascular-Kidney-Metabolic Health Initiative is made possible by Founding Sponsors Novo Nordisk and Boehringer Ingelheim, Supporting Sponsors Novartis Pharmaceuticals Corporation and Bayer, and Champion Sponsor DaVita. PAID ADVERTISEMENT © 2026 American Heart Association, Inc., a 501(c)(3) not-for-profit. All rights reserved. Unauthorized use prohibited. 9/26 WF1772201 VISIT CKM HEALTH LEARNING LAB Heart.org/CKMHProfessional WF-1772201 CKM Scientific Sessions Print Ads-_2026-5.indd 4 9/22/26 9:37 AM OPENING SESSION continued from page 1

8 SCIENTIFIC SESSIONS DAILY NEWS | Sunday, Nov. 8, 2026 People facing a fork in the road cannot be sure which road will lead to better outcomes. This is as true for clinical decisions as it is for career choices. But the tools of econometrics can help us make better decisions in both domains. Joshua Angrist, PhD, Ford professor of economics at the Massachusetts Institute of Technology and recipient of the 2021 Nobel Prize for Economics, will discuss these econometric tools in Sunday’s Nobel Laureate Address, “Mostly Harmless Instrumental Variables in Economics and Medicine.” His talk will focus on instrumental variable applications, part of the work on causal relationships for which he shared the 2021 prize with Guido W. Imbens, PhD, the Applied Econometrics professor and professor of economics, emeritus, at the Stanford Graduate School of Business. David Card, PhD, Class of 1950 professor emeritus of economics at the University of California, Berkeley, received the other half of the prize for his empirical contributions to labor economics. Angrist defined econometrics as the social science that turns data and theory into information useful to anyone facing a fork in the road. “Our econometric toolkit has the power to answer causal questions involving potential counterfactual outcomes; in other words, the outcomes that lie at the end of a road not taken.” Angrist drew an analogy between natural experiments and randomized trials. He said a natural experiment involves variation produced by chance events or human institutions in a way that can resemble randomization. He said many randomized controlled trials (RCTs) are similar in that they randomize access to an opportunity, an invitation or eligibility for treatment. In such trials, doctors and patients have some discretion following random assignment. An instrumental variable is a source of variation that affects the likelihood of receiving an intervention and, under specific assumptions, can be used to estimate the intervention’s causal effect on an outcome. The Vietnam-era draft lottery illustrates the application of instrumental variables in a natural experiment. In this case, Angrist said randomly assigned drafteligibility determined — partly, though not completely — the likelihood of conscription for service in the Vietnam era. Angrist used this to estimate causal effects of military service on veterans’ civilian earnings. Instrumental variables reveal this causal effect for a particular group, known as compliers: people who served when they were draft-eligible but would not have served otherwise. “This group is defined by the causal effect of the lottery on their service,” Angrist said. Angrist, Imbens and co-author Donald B. Rubin, PhD, John L. Loeb professor of statistics, emeritus, at Harvard University, formalized this concept within an instrumentalvariable framework. Angrist said this work expands the econometric theory behind instrumental variables. In the draft lottery example, the instrumental variable is draft eligibility status randomly assigned to birthdays. On the theory side, Angrist and Imbens embedded instrumental variables methods in the potential outcomes framework pioneered by Rubin. “[Instrumental variable] methods allow us to capture the causal effects of interventions like conscription that cannot be directly randomized in an RCT,” Angrist said. “However, the instrumental variable framework can be applied to RCTs as well. Many trials are closer to the messy draft lottery problem than to the pristine trials you likely encountered in stats class.” In Sunday’s presentation, Angrist will explain how econometrics and instrumental variables methods can be applied to the ISCHEMIA trial, an international randomized trial comparing initial invasive and conservative treatment strategies in patients with chronic coronary disease and moderate or severe ischemia. “Natural experiments like the draft lottery and strategy trials like ISCHEMIA are econometric twins,” he said. “The instrumental variable framework offers powerful and flexible tools for analysis of messy RCTs, including trials like ISCHEMIA with dynamic compliance.” Nobel Laureate: Outcomes at the end of the road not taken Econometric tools can help untangle knotty questions of cause and effect in medicine. Joshua Angrist, PhD UPCOMING SESSION Nobel Laureate Address 9:45–11 a.m. | Sunday, Nov. 8 S100A Clinicians urged to view CTEPH as part of the disease continuum that begins with acute pulmonary embolism. Treat the immediate, lifethreatening outcomes of pulmonary embolism (PE) first, but then quickly turn your attention to the long-term complications that may follow. That advice will shape Sunday’s session, “Optimizing Outcomes in Acute Pulmonary Embolism and Right Ventricular Shock Through Multidisciplinary Care.” During the session, panelist Irene Lang, MD, will delve into one specific complication: chronic thromboembolic pulmonary hypertension (CTEPH). Lang is a clinical cardiologist and professor of vascular biology at the Medical University of Vienna in Austria. Her presentation, “Beyond the Acute Event: CTEPH as a Sequela of Pulmonary Embolism,” examines this serious form of pulmonary hypertension caused by persistent, organized blood clots in the pulmonary arteries. It is increasingly being recognized as part of a disease continuum that begins with acute PE, she said. The condition is characterized by chronic fibrotic clot material that forms ring-like stenoses, webs and complete or partial arterial blockages despite at least three months of therapeutic anticoagulation. “In more than 60% of cases, a thromboembolic history can be tracked,” she said. “In parallel, a secondary microvasculopathy is observed that resembles a classical pulmonary arteriopathy.” In her presentation, Lang emphasizes the importance of multidisciplinary management for intermediate-high and highrisk PE patients, particularly those presenting with right ventricular (RV) dysfunction or hemodynamic instability. The hidden risks after PE Irene Lang, MD UPCOMING SESSION Optimizing Outcomes in Acute Pulmonary Embolism and Right Ventricular Shock Through Multidisciplinary Care 3:30–4:45 p.m. | Sunday, Nov. 8 S405A See PULMONARY EMBOLISM, page 14 Need a new profile pic? We’ve got you — free pro headshots. Visit the Headshot Lounge in the Science & Technology Hall, Heart Hub 10 Scan to sign up Sponsored by

10 SCIENTIFIC SESSIONS DAILY NEWS | Sunday, Nov. 8, 2026 134 Puppy Snuggles 3429 802 Eli Lilly and Company HIP 3 HIP 4 HIP 8 3414 Park Strip Sponsored by AstraZeneca 3102 NewAmsterdam Pharma Clinical Case Arena 3402 HIP 2 HIP 20 HIP 5 HIP 7 1302 Bridgebio HIP 1 HIP 11 HIP 12 HIP 13 HIP 14 HIP 15 HIP 16 HIP 17 HIP 18 HIP 19 2418 Kiniksa Pharmaceuticals HIP 9 HIPod 1 HIPod 2 HIPod 5 HIPod 6 HIPod 7 HIPod 8 HIPod 3 HIPod 4 1102 Duke Clinical Research Institute 911 Regeneron Pharmaceuticals, Inc. 711 Heartflow 2812 Edgewise Therapeutics 1217 AstraZeneca 126 Food Is Medicine Pavilion 2235 Boehringer Ingelheim Pharmaceuticals, Inc. 1019 ZOLL Medical Corporation 1908 Bayer 2218 Kardigan 2818 Alnylam Pharmaceuticals 616 Amgen 627 BMS/J&J Alliance 806 Cytokinetics 1014 117 Park Strip Sponsored by Novartis 120 Simulation Zone 1212 Bristol Myers Squibb 1602 1608 Pfizer 1612 Medtronic 1615 Novartis Pharmaceuticals Corporation 2102 Boehringer Ingelheim Pharmaceuticals, Inc. 2208 Novo Nordisk, Inc. 2223 Merck & Co., Inc. 2229 CRISPR Therapeutics 2402 Mineralys Therapuetics, Inc. 2614 Arrowhead Pharmaceuticals 2802 Ionis Pharmaceuticals, Inc. 2807 Viatris 3010 Edwards Lifesciences 3014 Idorsia Pharmaceuticals US Inc. 1206 Eli Lilly and Company 3207 American College of Cardiology 623 Milestone Pharmaceuticals 631 Bayer Heart Hub 602 Mayo Clinic Community Partners Health Innovation Pavilion Heart Theater 1 Global Quality Pavilion 13 12 Cardio Talk 1 11 Headshot Lounge Sponsored by Cedars-Sinai 10 HeartQuarters 1 Engagement Lounge Supported by Eli Lilly 2 11 4 Cardio Talk 2 Charging Lounge Sponsored by Novartis 3 Merck & Co., Inc. Sponsored by AstraZeneca Poster Attendant Booth Poster Hall Main Entrance Grand Concourse Escalator/stairs to/from Cafe 100 Publishers Row American Heart Association Scholars Posters 3702 3320 434 435 436 437 3219 3220 2630 534 537 2631 2632 3213 3214 3020 3119 3120 2607 2710 1017 3313 3314 26332634 2012 2112 3211 3215 3315 707 713 26092610 26282629 2707 2709 3007 3018 3019 3107 3118 3210 3216 3218 3310 3311 3316 3318 3319 636 736 737 607 2232 23322333 2233 2428 2429 2430 2432 2530 2531 2532 25282529 Wolters Kluwer 712 611 Science & Technology Hall Map

11 #ScientificSessions26 ScientificSessions.org 2845 B56 B57 B32 B38 B39 B3 Alnylam Pharmaceuticals B30 B31 Learning Lab: CKM Health 2446 Esperion Therapeutics 2847 3243 Testing & Awareness Lp(a), hsCRP & uACR B6 B29 B5 B50 B42 B43 B44 Learning Studio 5 B16 B17 B18 B48 B49 B47 B58 2240 B9 546 Learning Lab: Pfizer B26 B27 B28 B7 Novartis Pharmaceuticals Corporation B4 Exhibitor Lounge and Sales Office B40 B41 B8 2246 Cleveland Clinic 2645 Learning Studio 4 Learning Studio 1 B19 B2 Bristol Myers Squibb B20 B13 B14 B15 2640 CKM Health B1 Kardigan B10 B11 B12 Learning Studio 2 Learning Studio 3 2945 Mission Advancement 8 Charging Lounge Sponsored by AstraZeneca 9 7 Heart Theater 2 FAHA Lounge 5 Member Lounge Supported by Arrowhead 6 Boehringer Ingelheim Pharmaceuticals, Inc. Business Suites Escalator/stairs to/from Cafe LIB Therapeutics Bistro S31 Eli Lilly and Company Novartis Pharmaceuticals Corporation 543 544 441 442 443 28422843 30403041 B55 B33 B34 444 440 2940 2941 2942 2943 30423043 3141 3142 3143 B52 B53 B54 B51 540 B45 B46 3140 B21 B22 B23 B24 B25 B35 B36 B37 28402841 640 641 643 646 647 648 744 642 644 645 740 742 743 745 747 748 Science & Technology Hall Hours Sunday, Nov. 8 9 a.m.–4:30 p.m. Monday, Nov. 9 9 a.m.–3 p.m. Download the Mobile Meeting Guide App for interactive maps. See more #ScientificSessions26 highlights Scientific Sessions Conference Coverage sessions.hub.heart.org

12 SCIENTIFIC SESSIONS DAILY NEWS | Sunday, Nov. 8, 2026 Abbott . . . . . . . . ......... HIP 8, Simulation Zone Abcentra . . . . . . . . . . . ............ HIP Pod 6, B13 ADInstruments . . . . . . . . . . . . .............. 2332 AdventHealth Research Institute . . . . ...... 2333 Agepha Pharma FZ-LLC . . . . . . . . .......... 2607 Alexion, AstraZeneca Rare Disease . . . . ..... B34 AliveCor . . . . . . . . . . . . . . . ................. HIP 1 Alnylam Pharmaceuticals . . . . . . ....... 2818, B3 Amarin Pharma, Inc. . . . . . . . . . . ........... 2112 American Academy of Periodontology Foundation . . . . . . . ....... 3218 American College of Cardiology . . . . ...... 3207 American College of Physicians/ Annals of Internal Medicine . . . . . . ...... 3314 American Heart Association AI Assessment Lab . . . . . . . . . ......... HIP 15, B28 American Association of Heart Failure Nurses . .. 3311 American Heart Association Coffee Break . . 1014 American Heart Association Nation of Lifesavers . . . . . . . . . .......... 2645 American Kidney Fund . . . . . . . . . .......... 2843 Amgen . . . . . . . . . . . . .............. 616, B19, B20 AOP Health US . . . . . . . . . . . . . .............. 736 Arrowhead Pharmaceuticals . . . . . . . ....... 2614 AskBio – a Bayer Cell & Gene Therapy Platform Company . . . . ...... B53 Association of Black Cardiologists . . . . ..... 3318 AstraZeneca . . . . . ...... 1217, B10, B25, B26, B33 Athelas . . . . . . . . . . . . . . . ................. 2530 Auxira Health . . . . . . . . . . . ............ HIP Pod 5 Banner Health . . . . . . . . . . . . .............. 2630 Bayer . . . 631, 1908, B15, B32, B51, B52, B54, B55, B56 Biobeat . . . . . . . . . . . . . . . . ................. 636 BMS/J&J Alliance . . . . . . . . ......... 627, B11, B12 Boehringer Ingelheim Pharmaceuticals, Inc. . . . .... 2102, 2235, 2240, . . . . . . . . . . . . . .............. B17, B18, B47, B48 Boston Scientific . . . . . . . . .......... Simulation Zone Braveheart Bio . . . . . . . . . . ............ 3019, B36 Bridgebio . . . . . . . . ......... 1302, B21, B22, B38 Bristol Myers Squibb . . . . . . . . . ......... 1212, B2 Cambrian Health . . . . . . . . . . . . . . . . . . . . . . . 2634 Cardio Flow Design Inc. . . . . . . . . ......... HIP 14 Cardiosense . . . . . . . . . . . . . . ............... 748 Caristo Diagnostics . . . . . . . . . . . ............ 607 CB Innovations . . . . . . . . . . . . . .............. 611 CKM Health . . . ..... 2640, Learning Lab 2- 2945 Cleerly Inc. . . . . . . . . . . . . ............. HIP Pod 8 Cleveland Clinic . . . . . . . . . . . . ............. 2246 Corcept Therapeutics . . . . . . . . . . ........... 707 CRISPR Therapeutics . . . . . . . . . . ........... 2229 Cytokinetics . . . . . . . . . . . . . . ............... 806 DiaPharma Group . . . . . . . . . . . ............ 3118 Duke Clinical Research Institute . . . . . ...... 1102 ECD Global Alliance . . . . . . . . . . ........... 3316 Echo IQ . . . . . . . . . . . ............. HIP Pod 1, B35 Edgewise Therapeutics . . . . . ...... 2812, B57, B58 Edwards Lifesciences . . . . . . . . . . .......... 3010 Eli Lilly and Company . . . . . ...... 802, 1206, S31 Elucid . . . . . . . . . . . . . . . . . ................. 3018 Endless Dx . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 437 Erlanger Health . . . . . . . . . . . . .............. 744 Esperion Therapeutics . . . . . . . ........ 2446, B14 Exhibitor Lounge and Sales Office . . . . ....... B4 Fair Medical Hire . . . . . . . . . . . ............ HIP 17 Family Heart Foundation . . . . . . . . ......... 2428 FDA - Bad Ad Program . . . . . . . . . .......... 3219 Food Is Medicine . . . . . . . . . . . . ............. 126 Foresee Pharmaceuticals . . . . . . . . . ......... 713 Foundation for Sarcoidosis Research . . . .... 3220 Frontiers Media SA . . . . . . . . . . . . . . . . . . . . . . 2609 FUJIFILM VisualSonics . . . . . . . . . . .......... 2012 Genentech . . . . . . . . . . . . ............ 2432, B27 Global Learning Collaborative . . . . . . ....... 642 Google . . . . . . . . . . . . . . . ................. HIP 2 HealthSeers, Inc. . . . . . . . . . . . ............ HIP 11 Heart Lung AI . . . . . . . . . . . . . . .............. 641 Heartflow, Inc. . . . . 711, 1017, B45, Simulation Zone Hypertrophic Cardiomyopathy Association . 2707 Idorsia Pharmaceuticals US Inc. . . . . . ...... 3014 Imbria Pharmaceuticals . . . . . . . . . ......... 3119 ImpediMed . . . . . . . . . . . . . . ................ 737 Indiana University School of Nursing . . . .... 3313 Intellia Therapeutics . . . . . . . ....... 2233, B6, B8 InterAmerican Heart Foundation . . . . . ..... 3214 Intermountain Health . . . . . . . . . . ........... 648 Ionis Pharmaceuticals, Inc. . . . ... 2802, B41, B42 JAMA Network . . . . . . . . . . . . . .............. 537 Jiangsu Tingsn Technology Co., Ltd. . . . .... HIP 9 Johnson & Johnson Medtech . . . . ....Simulation Zone Kaneka - LIPOSORBER . . . . . . . . . . .......... 712 Kardigan . . . . . . . . . . . . . . .............. 2218, B1 Kiniksa Medical Pharmaceuticals . . . . . ...... B23 Kiniksa Pharmaceuticals . . . . . . . . ......... 2418 Lexeo Therapeutics, Inc. . . . . . . . . .......... 2430 LIB Therapeutics . . . . . . . . . . . . ............. 540 MannKind . . . . . . . . . . . . . . . ............... 3210 Mayo Clinic . . . . . . . . . . . . .............. 602, B9 mdgroup . . . . . . . . . . . . . . . ................ 2529 MDisrupt . . . . . . . . . . . . . . ................ HIP 13 Med Learning Group . . . . . . . . . . ............ 434 Mediwhale . . . . . . . . . . . . . . ................ 743 Medsignals . . . . . . . . . . . . . . ............... 2531 Medtronic . . . . . . . ........ 1612, Simulation Zone Mentice, Inc. . . . . . . . . .......... Simulation Zone Merck & Co., Inc. . . .... 1602, 2223, B40, B49, B50 Metabolic Endocrine Education Foundation . .. 3215 MetwareBio . . . . . . . . . . . . . ............... 2709 Milestone Pharmaceuticals . . . . . . . ......... 623 Mineralys Therapeutics, Inc. . . . . ...... 2402, B31 Modivcare . . . . . . . . . . . . . . ................ HIP 7 New York Life Insurance . . . . . . . . .......... 2633 NewAmsterdam Pharma . . . . . . ....... 3102, B24 nference . . . . . . . . . . . . . . . ................ 2628 Nightingale Health . . . . . . . . . . . ............ 544 Noah Labs . . . . . . . . . . . . ............. HIP Pod 3 Nova in Silico . . . . . . . . . . . . . . ............... 644 Novartis Pharmaceuticals Corporation . . . . . . . ........ 1615, B7, B29, B30 Novo Nordisk, Inc. . . . . . . . . . ........... 2208, B5 OBiO TECH, INC . . . . . . . . . . . . ............. 2528 Omron Healthcare, Inc . . . . . . . . . .......... 2232 Park Strip: AstraZeneca . . . . . . . . . ......... 3414 Park Strip: Novartis . . . . . . . . . . . ............ 117 Penumbra, Inc. . . . . . . . ......... Simulation Zone Pfizer . . . . . . . . . . . . 740, 1608, Learning Lab 1-546 PharmaSmart International . . . . . . ........ HIP 4 Photon Medics . . . . . . . . . . . . .............. 3020 Poster Attendant Booth . . . . . . . . .......... 3429 Propria LLC . . . . . . . . . . . . . . ............... 2429 Puppy Snuggles . . . . . . . . . . . . . ............. 134 QT Medical Inc. . . . . . . . . . . . . ............. 2710 Radcliffe Cardiology . . . . . . . . . . ........... 3107 Regeneron Medical Affairs . . . . . . ....... 911, B39 Research Diets, Inc. . . . . . . . . . . . ........... 2610 Sensor Bio . . . . . . . . . . . . .............. HIP Pod 4 Shaia Medical Heritage Apparel . . . . . ...... 2629 Sharecare . . . . . . . . . . . . . . ................ HIP 5 SleepImage . . . . . . . . . . . . . . ............... 747 SLIIIP Medical Group PA . . . . . . . . ......... HIP 12 StopAfib.org . . . . . . . . . . . . . ............... 3216 SurgeonsLab, Inc. . . . . . . ........ Simulation Zone Surgical Science, Inc . . . . . ...... Simulation Zone Sutter Health - Physician & APC Recruitment . .. 640 Syneos Health . . . . . . . . . . . . .............. 2532 Tabia Health . . . . . . . . . . . . .............. HIP Pod 2 Testing & Awareness: Lp(a), hsCRP & uACR . . . . . . . . .......... 3243 The Japanese Circulation Society . . . . . . . . . . 742 TIMI Study Group . . . . . . . . . . . ............ 3007 Topcon Healthcare . . . . . . . . . . .......... HIP 20 Ultromics . . . . . . . . . . . . . . . ................. 745 United Therapeutics . . . . . . . . . . ........... 3211 VHOS-ai srl . . . . . . . . . . . . . . ............... HIP 3 Viatris . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2807, B46 Viking Therapeutics . . . . . . . . .......... 3310, B37 Wolters Kluwer . . . . . . . . . . . . . .............. 534 Women As One . . . . . . . . . . . . ............. 3213 WuXi AppTec . . . . . . . . . . . . . ............... 543 Xenter . . . . . . . . . . . . . . . ................. HIP 16 Zelery Med-Corporation . . . . . . ....... HIP Pod 7 ZOLL Medical Corporation . . . . . . . . ........ 1019 2026 Exhibitors Welcome First-Time Exhibitors to Scientific Sessions! These companies are highlighted in red. Located in the Heart Hub CardioTalks . . . . . . . . . . . . . . . ............... 4, 11 Charging Lounges . . . . . . . . . . . . . .............. 3, 9 (Sponsored by Novartis and AstraZeneca) Engagement Lounge. . . . . . . . . . . . ............. 2 (Supported by Eli Lilly) FAHA Lounge. . . . . . . . . . . . . . . . ................ 5 Global Quality Showcase. . . . . . . . . . .......... 12 Headshot Lounge. . . . . . . . . . . . . . . . ............... 10 (Sponsored by Cedars-Sinai) Heart Theaters . . . . . . . . . . . . . .............. 7, 13 HeartQuarters. . . . . . . . . . . . . . . ................ 1 Member Lounge. . . . . . . . . . . . . . ............... 6 (Supported by Arrowhead) Mission Advancement. . . . . . . . . . . . ............ 8 Health Innovation Pavilion, Booth 100 | Simulation Zone, Booth 120 HIP = Health Innovation Pavilion

13 #ScientificSessions26 ScientificSessions.org Hypertension, Sodium and Sleep: An Integrated Approach to Cardiovascular Health Emerging research shows that blood pressure, sodium intake and sleep quality are closely interconnected. Addressing these factors together can improve patient outcomes and support comprehensive cardiovascular care. Explore educational topics, including: • How sodium intake—from both diet and prescription medications—affects blood pressure and cardiovascular risk • Practical approaches to reduce sodium exposure and enhance patient outcomes • Strategies for integrating sleep disorders screening and sleep health improvement • Cross-disciplinary insights and tools to support personalized care Expert-led podcasts, a clinical toolkit, and more, developed in collaboration with Brigham and Women's Hospital, will help you apply these strategies in practice. Scan now to find education and additional resources. © Copyright 2026 American Heart Association, Inc., a 501(c)(3) not-for-profit. All rights reserved. Unauthorized use prohibited. WF-1852240 9/26 Jazz Pharmaceuticals, Inc. is proud to support the American Heart Association’s Hypertension, Sodium and Sleep Professional Education Initiative. Paid Advertisement Cardiac computed tomography has long been an important tool for assessing coronary luminal stenosis, but recent advances are expanding its use to a more comprehensive evaluation of coronary inflammation, myocardial tissue characteristics and disease processes particularly relevant to women. A Sunday joint session with the American Heart Association and the Society of Cardiovascular Computed Tomography, “New Horizons in Cardiac Computed Tomography: American Heart Association Joint Session With Society of Cardiovascular Computed Tomography,” will explore this evolution by highlighting how advances in cardiac CT can improve risk assessment, refine diagnosis and potentially support more personalized patient management. Diana Litmanovich, MD, FNASCI, council chair of the Cardiovascular Radiology and Intervention Council, is moderating the session. She is an associate professor of radiology at Harvard Medical School in Boston. Litmanovich said the session will highlight three complementary areas involving emerging imaging biomarkers and techniques that may improve disease characterization and enhance risk stratification: • Pericoronary adipose tissue attenuation • CT-based myocardial tissue characterization • Imaging of spontaneous coronary artery dissection (SCAD) Litmanovich, who is also vice chair of practitioner and population health at Beth Israel Deaconess Medical Center in Boston, said pericoronary adipose tissue attenuation is an emerging biomarker that provides insight into coronary inflammation and may offer information about coronary atherosclerotic activity beyond conventional anatomic assessment. “It represents a shift toward characterizing the biological activity of coronary artery disease, rather than simply measuring the degree of luminal narrowing,” she said. Litmanovich said this part of the discussion will highlight the gap between research applications and clinical use, focusing on two main questions: • Can coronary artery CT tell us something about the activity and vulnerability of atherosclerotic disease beyond what we see in the lumen and plaque? • Can inflammation be detected when the coronary lumen appears to be normal? In the area of CT-based myocardial tissue characterization, Litmanovich said advances in CT acquisition, reconstruction and quantitative analysis are expanding the potential to characterize myocardial tissue beyond conventional morphology and function. “These developments may improve the evaluation of myocardial disease, complement cardiac MRI and broaden the clinical applications of cardiac CT,” she said. Litmanovich, whose research focuses in part on cardiovascular disease in women, said greater understanding of its distinct presentations and mechanisms is driving interest in tailored imaging strategies, including those used for SCAD. “The session will address the role of cardiac imaging in evaluating Cardiac CT offers a clearer picture of CVD Diana Litmanovich, MD, FNASCI Advances in imaging move beyond coronary narrowing to reveal disease activity, characterize myocardial tissue and refine diagnosis. UPCOMING SESSION New Horizons in Cardiac Computed Tomography: American Heart Association Joint Session With Society of Cardiovascular Computed Tomography 3:30–4:45 p.m. | Sunday, Nov. 8 S104B See CARDIAC CT, page 17

14 SCIENTIFIC SESSIONS DAILY NEWS | Sunday, Nov. 8, 2026 Delta Dental is proud to collaborate with the American Heart Association’s Healthy Smiles, Healthy Hearts Initiative. Delta Dental is a registered trademark of Delta Dental Plans Association. Expand Your Understanding of the Dynamic Connection Between Oral and Cardiovascular Health Access our vodcast series, eModule, and other resources bringing the latest science and evidence-based strategies for you to learn about topics like patient safety, accurate blood pressure measurement, and how oral health can be associated with increased risk for cardiovascular disease and stroke risk. Multiple CE credits available, including ADA CERP. American Heart Association. Unauthorized use prohibited. WF-1928217 10/26 LEARN NOW PAID ADVERTISEMENT She recommends a structured treatment pathway that begins with rapid assessment, identification of shock or RV failure, activation of a Pulmonary Embolism Response Team (PERT), selection of an appropriate reperfusion strategy and ongoing reassessment after stabilization. Treatment options may include systemic thrombolysis, catheter-based thrombectomy, surgical embolectomy and extracorporeal membrane oxygenation (ECMO) support when needed, she said. “Multidisciplinary assessment is key when considering the optimization of ICU-level care and the escalating role of mechanical circulatory support and catheter-directed aspiration thrombectomy in stabilizing hemodynamically unstable patients,” she said. “Repeated assessments are also important, using clinical metrics, bedside echo, lactate, optimal timing of CDT and circulatory support early and generously.” According to Lang, clinicians should consider ECMO early for respiratory support rather than positive pressure ventilation in a hemodynamically unstable patient. If intubation is unavoidable, Lang said clinicians should use a tidal volume and respiratory rate without positive end-expiratory pressure to achieve a normal PCO2. Hypercapnia may cause pulmonary vasoconstriction and plateau pressures much lower than 30 cmH2O to limit the risk of adverse hemodynamic effects. Lang urges clinicians not to view acute high-risk PE and CTEPH as separate diseases, but as interconnected stages along the same clinical spectrum. She said clinicians should maintain a high index of suspicion for CTEPH when evaluating patients with severe PE and consider chronic thromboembolic disease even before pursuing advanced therapies. “CTEPH more often appears as massive PE than follows it,” she said. Beyond acute management, Lang underscores the need for structured follow-up care. In particular, she said, high-risk PE survivors should undergo clinical assessment and echocardiographic evaluation within three to six months after the acute event to monitor for the development of CTEPH. Although the condition remains relatively uncommon during long-term follow-up, evidence suggests that CTEPH may occur in approximately 0.8%-3% of patients who experience any acute pulmonary embolism. PULMONARY EMBOLISM continued from page 8 Hours: Sunday, Nov. 8 10 a.m.–3 p.m. Monday, Nov. 9 10 a.m.–3 p.m. Snuggle stress away at the Puppy Snuggle Zone Science & Technology Hall, Booth 134

RkJQdWJsaXNoZXIy MjI2NjI=